Efficacy and safety of oral anticoagulation in patients with cancer

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 137-140

  Bona, Robert D ^a   Hickey, Amy D ^b   Wallace, Donna M ^b  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VEIN THROMBOSIS;

EID: 0030756905     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657516     Document Type: Conference Paper

References (31)

1. Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, Ten Cate JW. Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer. N Engl J Med 1992; 327:1128-33.
2. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S. The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer. N Engl J Med 1988; 318:404-7.
3. Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J, for the National Cancer Instittue of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14:2731-37.
4. Ockelford PA, Patterson J, Johns AS. A Double-Blind Randomized Placebo Controlled Trial of Thromboprophylaxis in Major Elective General Surgery Using Once Daily Injections of a Low Molecular Weight Heparin Fragment (Fragmin). Thromb Haemost 1989; 62:1046-49.
5. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, Goodwin P. Double Blind Randomised Trial of Very Low Dose Warfarin for Prevention of Thromboembolism in Stage IV Breast Cancer. Lancet 1994; 343:886-9.
6. Cohen JR, Tenenbaum N, Citron M. Greenfield filter as a primary therapy for venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991; 109:12-5.
7. Calligaro KD, Bergen WS, Haut MJ, Savarese RP, DeLaurentis DA. Thromboembolic Complications in Patients with Advanced Cancer: Anticoagulation Versus Greenfield Filter Placement. Ann Vasc Surg 1991; 5:186-9.
8. Schwarz RD, Marrero AM, Conlon KC, Burt M. Inferior Vena Cava Filters in Cancer Patients: Indications and Outcome. J Clin Oncol 1996; 14:652-7.
9. Zacharski LR, Henderson WG, Forman WB, Edwards RL, Cornell CJ, Forcier RJ, Headley E, Kim S, O'Donnell JF, O'Dell R, Tornyos K, Kwaan HC. Bleeding Complications from Warfarin Anticoagulation in Patients with Malignancy. J of Med 1985; 16:535-61.
10. Krauth D, Holden A, Knapic N, Liepman M, Ansell J. Safety and Efficacy of Long-Term Oral Anticoagulation in Cancer Patients. Cancer 1987; 59:983-5.
11. Wester, JPJ, deValk HW, Nieuwenhuis HK, Brouwer CB, van der Graaf Y, Meuwissen OJATh, Hart HC, Sixma JJ, Banga JD. Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism.Thromb Haemost 1996; 76:682-8.
12. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and Preliminary Validation of Predictors of Major Bleeding in Hospitalized Patients Starting Anticoagulant Therapy. Am J Med 1987; 82:703-13.
13. Landefeld CS, McGuire E, Rosenblatt MW. A Bleeding Risk Index for Estimating the Probability of Major Bleeding in Hospitalized Patients Starting Anticoagulant Therapy. Am J Med 1990; 89:569-78.
14. Landefeld CS, Beyth RJ. Anticoagulant-Related Bleeding: Clinical Epidemiology, Prediction, and Prevention. Am J Med 1993; 95:315-27.
15. Finh SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH, for the National Consortium of Anticoagulation Clinics. The Risk for and Severity of Bleeding Complcations in Elderly Patients Treated with Warfarin. Ann Intern Med 1996; 124:970-8.
16. Hylek EM, Singer DE. Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin. Ann Intern Med. 1994; 120:897-902.
17. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Assessment of a Bleeding Risk Index in Two Cohorts of Patients Treated with Oral Anticoagulants. Thromb Haemost 1996; 76:12-6.
18. Landefeld CS, Goldman L. Major Bleeding in Outpatients Treated with Warfarin: Incidence and Prediction by Factors Known at the Start of Outpatient Therapy. Am J Med 1989; 87:144-52.
19. Finh SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH, for the Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993;118:511-20.
20. Chan A, Woodruff RK. Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. Aust NZ J Med 1992; 22:119-22.
21. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and Thromboembolism During Anticoagulant Therapy: A Population-Based Study in Rochester, Minnesota. Mayo Clin Proc 1995; 70:725-33.
22. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernard E, Prins MH. The Long Term Clinical Course of Acute Deep Venous Thrombosis. Ann Intern Med 1996; 125:1-7.
23. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The Efficacy and Safety of Oral Anticoagulation in Patients with Cancer. Thromb Haemost 1995; 74:1055-8.
24. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Beven EG, Bay JW. Treatment of Deep Vein Thrombosis and Pulmonary Emboli in Patients with Primary and Metastatic Brain Tumors. Arch Intern Med 1987; 147:2177-79.
25. Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O'Fallon JR. Thromboembolism in Patients with High-Grade Glioma. Mayo Clin Proc 1994; 69:329-32.
26. Schulman S, Rhedin A, Lindmarker P, Carlsson Am Larfars G, Nicol P, Loogna E, Svensson E, Ljunberg B, Walter H. Viering S, Nordlander S, Leijd B, Jonsson K, Hjorth M, Linder O, Boberg J, and the Duration of Anticoagulation Trial Study Group. A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy After A First Episode of Venous Thromboembolism. N Engl J Med 1995; 332:1661-5.
27. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal Duration of Oran Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. Thromb Haemost 1995; 74:606-11.
28. Research Committee of the British Thoracic Society. Optimum Duration of anticoagulant for deep-vein thrombosis and pulmonary embolism Lancet 1992; 340:873-6.
29. Moore FD, Osteen RT, Karp DD, Steele G, Wilson RE. Anticoagulants, Venous Thromboembolism, and the Cancer Patient. Arch Surg 1981; 116:405-7.
30. Clarke-Pearson DL, Synan IS, Creasman WT. Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Obstet Gynecol 1983; 147: 369-7.
31. Bell WR, Starksen NF, Tong S, Porterfield JK. Trousseau's Syndrome. Devastating Coagulopathy in the Absence of Heparin. Am J Med 1985; 79:423-30.